These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 16515310)
1. [The early therapy challenge]. Reichmann H Krankenpfl J; 2005; 43(7-10):240. PubMed ID: 16515310 [No Abstract] [Full Text] [Related]
2. Reexamination of the TEMPO Study. Shults CW Arch Neurol; 2005 Aug; 62(8):1320; author reply 1321. PubMed ID: 16087778 [No Abstract] [Full Text] [Related]
3. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Chen JJ; Swope DM; Dashtipour K Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186 [TBL] [Abstract][Full Text] [Related]
4. [Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment]. Oberpichler-Schwenk H Med Monatsschr Pharm; 2005 Jul; 28(7):224-7. PubMed ID: 16038119 [No Abstract] [Full Text] [Related]
5. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. Henchcliffe C; Schumacher HC; Burgut FT Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338 [TBL] [Abstract][Full Text] [Related]
6. Preclinical versus clinical neuroprotection. Grünblatt E; Schlösser R; Gerlach M; Riederer P Adv Neurol; 2003; 91():309-28. PubMed ID: 12442689 [No Abstract] [Full Text] [Related]
7. [Drug therapy of Parkinson's disease]. Myllylä V Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076 [No Abstract] [Full Text] [Related]
8. [Rasagiline in motor fluctuations]. Miletzki A Fortschr Neurol Psychiatr; 2005 Sep; 73(9):488. PubMed ID: 16217881 [No Abstract] [Full Text] [Related]
9. Rasagiline as a therapy for Parkinson's disease (PD). Hermanowicz N Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520 [No Abstract] [Full Text] [Related]
10. Clinical trials of neuroprotection for Parkinson's disease. LeWitt PA Neurology; 2004 Oct; 63(7 Suppl 2):S23-31. PubMed ID: 15477583 [No Abstract] [Full Text] [Related]
12. Rasagiline -- is there a place for this drug in managing Parkinson's disease? Sharma JC Int J Clin Pract; 2006 Feb; 60(2):132-3. PubMed ID: 16451281 [No Abstract] [Full Text] [Related]
13. [What strategies are recommended for early stage disease? Other treatments]. Damier P Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():105-8. PubMed ID: 10916044 [No Abstract] [Full Text] [Related]
14. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Guay DR Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539 [TBL] [Abstract][Full Text] [Related]
15. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Jenner P Neurology; 2004 Oct; 63(7 Suppl 2):S13-22. PubMed ID: 15477581 [No Abstract] [Full Text] [Related]
16. New drug treatment for Parkinson's disease. FDA Consum; 2006; 40(4):7. PubMed ID: 17245831 [No Abstract] [Full Text] [Related]
17. MAO-B inhibitor know-how: back to the pharm. Lewitt PA Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057 [No Abstract] [Full Text] [Related]
19. Drug selection and timing of initiation of treatment in early Parkinson's disease. Schapira AH; Olanow CW Ann Neurol; 2008 Dec; 64 Suppl 2():S47-55. PubMed ID: 19127579 [TBL] [Abstract][Full Text] [Related]